{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:17Z","timestamp":1792785077487,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0502200"],"award-info":[{"award-number":["2023ZD0502200"]}]},{"name":"National Natural Science Foundation of China","award":["82230058"],"award-info":[{"award-number":["82230058"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Joint innovative Fund of Beijing Natural Science Foundation and Changping District","award":["L234004"],"award-info":[{"award-number":["L234004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Effective predictive biomarkers for immunotherapy in breast cancer remain elusive, limiting precision treatment strategies. Although the biological significance of HER2\u2011low expression has gained increasing attention, its impact on immunotherapy response remains unknown. Here, we investigated the impact of HER2 expression on response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and explored the underlying biological patterns through comprehensive multi-omics analysis. A multi-center real-world cohort study revealed that HER2-low TNBC patients had poorer responses to immunotherapy than HER2-0 patients, whereas no significant difference was observed in chemotherapy alone; these findings were validated in independent prospective cohorts (ISPY-2 and NeoTRIP). Single\u2011cell multi\u2011omics further demonstrated that HER2\u2011low tumors exhibited reduced expression of major histocompatibility complex and immune checkpoint molecules, along with diminished T\u2011cell activity, relative to HER2\u20110 tumors. Following immunotherapy, HER2\u2011low tumors showed no significant downregulation of targeted immune checkpoint molecules and less pronounced T\u2011cell clonal remodeling. Collectively, these findings establish HER2\u2011low expression as a negative predictor of immunotherapy response, shaped by a less immunogenic tumor microenvironment. These results provide important insights into the distinct immunological features of HER2\u2011low triple\u2011negative breast cancer and warrant further mechanistic and clinical investigations.<\/jats:p>","DOI":"10.1038\/s41698-026-01562-3","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:55:13Z","timestamp":1781715313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Hewei","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1562_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1562_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Prim. 5, 66 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1562_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429\u20134434 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1562_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"1562_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study\u2729. Ann. Oncol. 33, 534\u2013543 (2022).","journal-title":"Ann. Oncol."},{"key":"1562_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl, S. et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 30, 1279\u20131288 (2019).","journal-title":"Ann. Oncol."},{"key":"1562_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"1562_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda, R. et al. Effect of Pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6, 676\u2013684 (2020).","journal-title":"JAMA Oncol."},{"key":"1562_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1562_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386, 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1562_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1562_CR12","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. HER2-low breast cancer: pathological and clinical landscape. J. Clin. Oncol. 38, 1951\u20131962 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1562_CR13","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J. Clin. Oncol. 38, 1887\u20131896 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1562_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cac2.12577","volume":"44","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study. Cancer Commun. 44, 833\u2013851 (2024).","journal-title":"Cancer Commun."},{"key":"1562_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert, C. et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 22, 1151\u20131161 (2021).","journal-title":"Lancet Oncol."},{"key":"1562_CR16","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.ctrv.2023.102538","volume":"115","author":"Y Ergun","year":"2023","unstructured":"Ergun, Y., Ucar, G. & Akagunduz, B. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis. Cancer Treat. Rev. 115, 102538 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"1562_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43324-w","volume":"14","author":"P Tarantino","year":"2023","unstructured":"Tarantino, P. et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat. Commun. 14, 7496 (2023).","journal-title":"Nat. Commun."},{"key":"1562_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang, G. et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 20, 142 (2022).","journal-title":"BMC Med."},{"key":"1562_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-024-02047-0","volume":"9","author":"Z Yi","year":"2024","unstructured":"Yi, Z. et al. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal Transduct. Target Ther. 9, 345 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"1562_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01639-y","volume":"25","author":"XE Hu","year":"2023","unstructured":"Hu, X. E. et al. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Breast Cancer Res. 25, 34 (2023).","journal-title":"Breast Cancer Res."},{"key":"1562_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621, 868\u2013876 (2023).","journal-title":"Nature"},{"key":"1562_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40, 609\u2013623.e606 (2022).","journal-title":"Cancer Cell"},{"key":"1562_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai, L. et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell 39, 989\u2013998 e985 (2021).","journal-title":"Cancer Cell"},{"key":"1562_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00465-3","volume":"8","author":"J Staaf","year":"2022","unstructured":"Staaf, J. et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. npj Breast Cancer 8, 94 (2022).","journal-title":"npj Breast Cancer"},{"key":"1562_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1562_CR26","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).","journal-title":"Sci. Signal"},{"key":"1562_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s43018-024-00725-0","volume":"5","author":"Y-Z Jiang","year":"2024","unstructured":"Jiang, Y.-Z. et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nat. Cancer 5, 673\u2013690 (2024).","journal-title":"Nat. Cancer"},{"key":"1562_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.6004\/jnccn.2018.7046","volume":"16","author":"CA Santa-Maria","year":"2018","unstructured":"Santa-Maria, C. A. & Nanda, R. Immune checkpoint inhibitor therapy in breast cancer. J. Natl. Compr. Cancer Netw. 16, 1259\u20131268 (2018).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"1562_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/CM9.0000000000000710","volume":"133","author":"J Zhao","year":"2020","unstructured":"Zhao, J. & Huang, J. Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1\/programmed cell death protein ligand-1. Chin. Med. J. 133, 853\u2013862 (2020).","journal-title":"Chin. Med. J."},{"key":"1562_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan, X. et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606, 791\u2013796 (2022).","journal-title":"Nature"},{"key":"1562_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).","journal-title":"Nat. Commun."},{"key":"1562_CR32","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e514 (2021).","journal-title":"Cell"},{"key":"1562_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"1562_CR34","doi-asserted-by":"publisher","first-page":"167880","DOI":"10.1016\/j.bbadis.2025.167880","volume":"1871","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., Yang, H., Jiang, Y., Jiang, Y. & Mao, R. Angiogenesis and immune microenvironment in triple-negative breast cancer: targeted therapy. Biochim. Biophys. Acta Mol. Basis Dis. 1871, 167880 (2025).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1562_CR35","doi-asserted-by":"publisher","first-page":"105186","DOI":"10.1016\/j.ebiom.2024.105186","volume":"105","author":"H Li","year":"2024","unstructured":"Li, H. et al. Clinical efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR-positive\/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. eBioMedicine 105, 105186 (2024).","journal-title":"eBioMedicine"},{"key":"1562_CR36","doi-asserted-by":"publisher","first-page":"104813","DOI":"10.1016\/j.critrevonc.2025.104813","volume":"214","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Unlock the code of MHC II-enabled cancer immunotherapy. Crit. Rev. Oncol. Hematol. 214, 104813 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1562_CR37","doi-asserted-by":"publisher","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor, B. C. & Balko, J. M. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front. Immunol. 13, 844866 (2022).","journal-title":"Front. Immunol."},{"key":"1562_CR38","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","volume":"25","author":"ML Axelrod","year":"2019","unstructured":"Axelrod, M. L., Cook, R. S., Johnson, D. B. & Balko, J. M. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. 25, 2392\u20132402 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1562_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1562_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01023-3","volume":"9","author":"AF Bedoya-L\u00f3pez","year":"2025","unstructured":"Bedoya-L\u00f3pez, A. F. et al. Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer. npj Precis. Oncol. 9, 287 (2025).","journal-title":"npj Precis. Oncol."},{"key":"1562_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66800-x","volume":"16","author":"L Meder","year":"2025","unstructured":"Meder, L. et al. ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer. Nat. Commun. 16, 10983 (2025).","journal-title":"Nat. Commun."},{"key":"1562_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35, 428\u2013440.e425 (2019).","journal-title":"Cancer Cell"},{"key":"1562_CR43","doi-asserted-by":"publisher","first-page":"zcac018","DOI":"10.1093\/narcan\/zcac018","volume":"4","author":"KJ Thompson","year":"2022","unstructured":"Thompson, K. J. et al. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer 4, zcac018 (2022).","journal-title":"NAR Cancer"},{"key":"1562_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1562_CR45","unstructured":"Vallon-Christersson, J. RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer. Mendeley Data V4, 10.17632\/yzxtxn4nmd.4 (2025)."},{"key":"1562_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell 43, 446\u2013463.e447 (2025).","journal-title":"Cancer Cell"},{"key":"1562_CR47","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593 e1578 (2021).","journal-title":"Cancer Cell"},{"key":"1562_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1562_CR49","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"1562_CR50","doi-asserted-by":"publisher","first-page":"e1012760","DOI":"10.1371\/journal.pcbi.1012760","volume":"21","author":"Q Yang","year":"2025","unstructured":"Yang, Q., Safina, K. R., Nguyen, K. D. Q., Tuong, Z. K. & Borcherding, N. scRepertoire 2: enhanced and efficient toolkit for single-cell immune profiling. PLoS Comput. Biol. 21, e1012760 (2025).","journal-title":"PLoS Comput. Biol."},{"key":"1562_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. F1000Res 9, 47 (2020).","journal-title":"F1000Res"},{"key":"1562_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1562_CR53","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01562-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01562-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01562-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:35:48Z","timestamp":1791239748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01562-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01562-3","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"371"}}